Pfizer Inc. has provided an update to
its development pipeline, which includes 118 programs from Phase 1 through
registration. The updated pipeline continues to reflect Pfizer’s ongoing
investment in high-priority disease areas with considerable unmet medical need.
“We
continue to be confident in the progression of our late-stage pipeline and have
advanced three compounds into registration since our last portfolio
update,” said Ian Read, president of Pfizer’s Worldwide Biopharmaceutical
Businesses. “We have a strong pipeline with programs in development across
important therapeutic areas including oncology, neuroscience and inflammation.
We remain committed to growing our biologics and vaccines development
programs.” “Building on the rapid integration of Pfizer and Wyeth,
the new Pfizer brings a wealth of scientific approaches and technologies to our
key investment areas, and we are developing novel product candidates across all
phases of development,” said Mikael Dolsten, MD, PhD, president of
Pfizer’s Worldwide Research and Development. “We are leveraging the best
product assets of our legacy organizations and driving important steps forward
in strategy and method to deliver a portfolio of next generation medicines and
vaccines.” Pfizer now has 118 programs in Phase 1 through registration,
compared to 133 programs at its last pipeline update in January, 2010. This reflects
25 programs that are new or have advanced along the pipeline and 31 programs
that have been discontinued since the last update.
The current pipeline includes 26 programs in Phase 3 and
nine programs in registration, as well as 27 biologics and four vaccines across
all phases of development.
